Suppr超能文献

新合成的含氟肉桂基哌嗪类化合物具有低体外 MAO-B 结合。

Newly Synthesized Fluorinated Cinnamylpiperazines Possessing Low In Vitro MAO-B Binding.

机构信息

ICTM-Department of Chemistry, University of Belgrade, Njegoševa 12, 11000 Belgrade, Serbia.

Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Permoserstraße 15, 04318 Leipzig, Germany.

出版信息

Molecules. 2020 Oct 26;25(21):4941. doi: 10.3390/molecules25214941.

Abstract

Herein, we report on the synthesis and pharmacological evaluation of ten novel fluorinated cinnamylpiperazines as potential monoamine oxidase B (MAO-B) ligands. The designed derivatives consist of either cinnamyl or 2-fluorocinnamyl moieties connected to 2-fluoropyridylpiperazines. The three-step synthesis starting from commercially available piperazine afforded the final products in overall yields between 9% and 29%. An in vitro competitive binding assay using l-[H]Deprenyl as radioligand was developed and the MAO-B binding affinities of the synthesized derivatives were assessed. Docking studies revealed that the compounds - were stabilized in both MAO-B entrance and substrate cavities, thus resembling the binding pose of l-Deprenyl. Although our results revealed that the novel fluorinated cinnamylpiperazines - do not possess sufficient MAO-B binding affinity to be eligible as positron emission tomography (PET) agents, the herein developed binding assay and the insights gained within our docking studies will certainly pave the way for further development of MAO-B ligands.

摘要

在此,我们报告了十种新型氟代肉桂基哌嗪的合成和药理学评价,这些化合物作为潜在的单胺氧化酶 B(MAO-B)配体。设计的衍生物由肉桂基或 2-氟肉桂基部分连接到 2-氟吡啶基哌嗪上。从商业可得的哌嗪开始的三步合成以 9%至 29%的总产率得到最终产物。开发了一种使用 l-[H]Deprenyl 作为放射性配体的体外竞争性结合测定法,并评估了合成衍生物的 MAO-B 结合亲和力。对接研究表明,化合物 - 在 MAO-B 入口和底物腔中均稳定,因此类似于 l-Deprenyl 的结合构象。尽管我们的结果表明,新型氟代肉桂基哌嗪 - 不具有足够的 MAO-B 结合亲和力作为正电子发射断层扫描(PET)剂,但在此开发的结合测定法和我们的对接研究中获得的见解肯定将为 MAO-B 配体的进一步开发铺平道路。

相似文献

1
Newly Synthesized Fluorinated Cinnamylpiperazines Possessing Low In Vitro MAO-B Binding.
Molecules. 2020 Oct 26;25(21):4941. doi: 10.3390/molecules25214941.
7
Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: Fluorinated chalcones of morpholine versus imidazole.
Arch Pharm (Weinheim). 2019 Apr;352(4):e1800309. doi: 10.1002/ardp.201800309. Epub 2019 Jan 21.
9
Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging.
Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1369-1382. doi: 10.1007/s00259-019-04305-8. Epub 2019 Mar 27.

引用本文的文献

1
Identification of New -methyl-piperazine Chalcones as Dual MAO-B/AChE Inhibitors.
Pharmaceuticals (Basel). 2023 Jan 6;16(1):83. doi: 10.3390/ph16010083.
2
First-in-Humans Evaluation of F-SMBT-1, a Novel F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis.
J Nucl Med. 2022 Oct;63(10):1551-1559. doi: 10.2967/jnumed.121.263254. Epub 2022 Jan 27.

本文引用的文献

2
Synthesis and preclinical evaluation of [F]FSL25.1188, a reversible PET radioligand for monoamine oxidase-B.
Bioorg Med Chem Lett. 2019 Jul 1;29(13):1624-1627. doi: 10.1016/j.bmcl.2019.04.040. Epub 2019 Apr 27.
3
Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging.
Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1369-1382. doi: 10.1007/s00259-019-04305-8. Epub 2019 Mar 27.
4
Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update.
Med Res Rev. 2019 Sep;39(5):1603-1706. doi: 10.1002/med.21561. Epub 2019 Jan 2.
5
Nuclear medicine of the cerebellum.
Handb Clin Neurol. 2018;154:251-266. doi: 10.1016/B978-0-444-63956-1.00015-1.
8
Strategies to facilitate the discovery of novel CNS PET ligands.
EJNMMI Radiopharm Chem. 2017;1(1):13. doi: 10.1186/s41181-016-0016-2. Epub 2016 Sep 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验